Dashboard
Manage Tickers

TNYA Tenaya Therapeutics, Inc.

Nasdaq tenayatherapeutics.com


$ 1.35 $ -0.03 (-2.17 %)    

Thursday, 06-Nov-2025 15:59:54 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 612.39 $ -10.09 (-1.62 %)
DIA $ 469.75 $ -2.78 (-0.59 %)
SPY $ 671.21 $ -6.30 (-0.93 %)
TLT $ 89.78 $ 0.21 (0.23 %)
GLD $ 365.97 $ -1.11 (-0.3 %)
$ 1.38
$ 1.38
$ 1.34 x 214
$ 1.36 x 800
$ 1.34 - $ 1.42
$ 0.36 - $ 4.01
2,823,412
na
224.91M
$ 2.51
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-06-2025 06-30-2025 10-Q
2 05-07-2025 03-31-2025 10-Q
3 03-10-2025 12-31-2024 10-K
4 11-06-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-14-2024 03-31-2024 10-Q
7 03-18-2024 12-31-2023 10-K
8 11-08-2023 09-30-2023 10-Q
9 08-09-2023 06-30-2023 10-Q
10 05-10-2023 03-31-2023 10-Q
11 03-08-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-10-2022 06-30-2022 10-Q
14 05-11-2022 03-31-2022 10-Q
15 03-23-2022 12-31-2021 10-K
16 11-10-2021 09-30-2021 10-Q
17 09-08-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

tenaya-therapeutics-to-give-two-late-breaking-oral-presentations-at-the-american-heart-association-2025-scientific-sessions-taking-place-november-7-10-2025
Tenaya Therapeutics To Give Two Late-break...
11/04/2025 22:39:21

Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver...

top-4-biotech-stocks-set-for-a-breakout-momentum-scores-surge
Top 4 Biotech Stocks Set For A Breakout: M...
09/08/2025 09:59:39

Several biotech stocks are showing renewed strength over the past week, with their Momentum scores soaring in Benzinga's Ed...

hc-wainwright--co-reiterates-buy-on-tenaya-therapeutics-maintains-5-price-target
HC Wainwright & Co. Reiterates Buy on Tena...
09/02/2025 10:51:49

HC Wainwright & Co. analyst Joseph Pantginis reiterates Tenaya Therapeutics (NASDAQ:TNYA) with a Buy and maintains $5 pr...

reported-sunday-tenaya-highlights-urgent-need-for-disease-modifying-approaches-in-pediatric-mybpc3-associated-hcm-based-on-myclimb-interim-findings
Reported Sunday, Tenaya Highlights Urgent ...
09/02/2025 07:42:02

Largest Noninterventional Natural History Study of People Under 18 with MYBPC3-associated HCM with More than 200 Participants93...

hc-wainwright--co-reiterates-buy-on-tenaya-therapeutics-maintains-5-price-target
HC Wainwright & Co. Reiterates Buy on Tena...
08/27/2025 10:15:07

HC Wainwright & Co. analyst Joseph Pantginis reiterates Tenaya Therapeutics (NASDAQ:TNYA) with a Buy and maintains $5 pr...

chardan-capital-maintains-buy-on-tenaya-therapeutics-maintains-9-price-target
Chardan Capital Maintains Buy on Tenaya Th...
08/07/2025 12:50:49

Chardan Capital analyst Geulah Livshits maintains Tenaya Therapeutics (NASDAQ:TNYA) with a Buy and maintains $9 price target.

tenaya-therapeutics-q2-eps-014-beats-017-estimate
Tenaya Therapeutics Q2 EPS $(0.14) Beats $...
08/06/2025 21:13:47

Tenaya Therapeutics (NASDAQ:TNYA) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $...

tenaya-therapeutics-completes-enrollment-in-mypeak-1-trial-for-hcm-and-initiates-ridge-1-trial-for-arvc-with-dsmb-endorsements
Tenaya Therapeutics Completes Enrollment I...
07/30/2025 12:36:30

Enrollment in Both Dose Cohorts of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Hypertrophic Cardiomyopathy (HCM) Comp...

chardan-capital-maintains-buy-on-tenaya-therapeutics-maintains-9-price-target
Chardan Capital Maintains Buy on Tenaya Th...
05/09/2025 10:53:51

Chardan Capital analyst Geulah Livshits maintains Tenaya Therapeutics (NASDAQ:TNYA) with a Buy and maintains $9 price target.

tenaya-therapeutics-q1-eps-024-misses-020-estimate
Tenaya Therapeutics Q1 EPS $(0.24) Misses ...
05/07/2025 21:26:32

Tenaya Therapeutics (NASDAQ:TNYA) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of...

hc-wainwright--co-reiterates-buy-on-tenaya-therapeutics-maintains-5-price-target
HC Wainwright & Co. Reiterates Buy on Tena...
04/25/2025 11:36:16

HC Wainwright & Co. analyst Joseph Pantginis reiterates Tenaya Therapeutics (NASDAQ:TNYA) with a Buy and maintains $5 pr...

tenaya-therapeutics-reveals-interim-data-from-ridge-natural-history-and-seroprevalence-study-of-adults-with-pkp2-associated-arvc-at-heart-rhythm-2025
Tenaya Therapeutics Reveals Interim Data f...
04/24/2025 18:23:13

hc-wainwright--co-reiterates-buy-on-tenaya-therapeutics-maintains-5-price-target
HC Wainwright & Co. Reiterates Buy on Tena...
03/31/2025 14:38:23

HC Wainwright & Co. analyst Joseph Pantginis reiterates Tenaya Therapeutics (NASDAQ:TNYA) with a Buy and maintains $5 pr...

tenaya-therapeutics-announces-late-breaker-presentation-of-new-data-from-mypeak-1-phase-1b2-clinical-trial-of-tn-201-at-american-college-of-cardiology-annual-meeting
Tenaya Therapeutics Announces Late Breaker...
03/31/2025 14:06:40

TN-201 Has Been Well Tolerated at 3E13 vg/kg DoseNew Biopsy Data Reaffirm Robust Transduction and RNA Expression with TN-201; R...

tenaya-therapeutics-approves-restructuring-plan-restructuring-plan-to-reduce-cash-expenses-restructuring-plan-to-extend-cash-runway-into-h2-2026-to-reduce-workforce-under-restructuring-plan-to-incur-16m-27m-in-restructuring-charges-expects-to-recognize-charges-by-q3-2025
Tenaya Therapeutics Approves Restructuring...
03/28/2025 20:44:10

- SEC Filing

tenaya-announces-preclinical-data-for-tn-201-gene-therapy-in-nature-communications-mybpc3-gene-replacement-shows-dose-dependent-mybp-c-protein-increase-reverses-left-ventricular-hypertrophy-tn-201-in-phase-1b2-trial-for-mybpc3-associated-hypertrophic-cardiomyopathy
Tenaya Announces Preclinical Data For TN-2...
03/24/2025 12:33:15

Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver...

tenaya-therapeutics-files-for-mixed-shelf-offering-of-up-to-300m
Tenaya Therapeutics Files For Mixed Shelf ...
03/21/2025 20:13:22

- SEC Filing

tenaya-therapeutics-announced-presentation-of-tn-201-gene-therapy-data-for-mybpc3-associated-hypertrophic-cardiomyopathy-at-acc-2025-in-chicago-includes-1-year-patient-assessments-from-mypeak-1-phase-1b2-trial
Tenaya Therapeutics Announced Presentation...
03/19/2025 12:37:31

Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver...

canaccord-genuity-maintains-buy-on-tenaya-therapeutics-lowers-price-target-to-6
Canaccord Genuity Maintains Buy on Tenaya ...
03/13/2025 16:13:44

Canaccord Genuity analyst Whitney Ijem maintains Tenaya Therapeutics (NASDAQ:TNYA) with a Buy and lowers the price target fr...

morgan-stanley-maintains-overweight-on-tenaya-therapeutics-lowers-price-target-to-5
Morgan Stanley Maintains Overweight on Ten...
03/12/2025 13:03:25

Morgan Stanley analyst Matthew Harrison maintains Tenaya Therapeutics (NASDAQ:TNYA) with a Overweight and lowers the price t...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION